# A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.

> **NCT05407220** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP1904-1
- **DRUG:** HCP1904-3

## Key facts

- **NCT ID:** NCT05407220
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-29
- **Primary completion:** 2022-07-25
- **Final completion:** 2022-07-25
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05407220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05407220, "A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05407220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*